Excipient qualification for Indian formulators

Multi-compendial excipients simplify filings only when the supporting documentation is complete. A practical view of what a formulation team should collect before first use.

An excipient that claims IP, BP, USP and EP compliance is useful only if the certificate of analysis demonstrates testing against each claimed monograph, or clearly states which monograph the batch was released against. Formulation teams routinely discover the difference during a regulatory query rather than during qualification.

Before first use, collect the certificate of analysis, the material safety data sheet, the manufacturing site declaration, an elemental impurities statement, a residual solvents statement and the change control commitment. Together these cover the majority of queries raised during filings and customer audits.

Change control is the field most often overlooked. An excipient supplier that changes a raw material source, a process step or a site without notification creates a variation risk that the formulator carries. Written notification commitments should form part of the supply agreement, not the purchase order.

Where an excipient is used in a product intended for regulated export markets, plan an on-site audit early. Documentation gaps are cheaper to resolve before commercial batches than after.